Life Science News

RSS

Daylight Solutions launches world's first laser-based infrared microscopy platform

Daylight Solutions, Inc., a leading manufacturer of molecular detection and imaging solutions in the mid-infrared, today announced the launch of the world's first commercially available laser-based infrared microscopy platform.

From Daylight Solutions Inc 19 Mar 2014

ChromaTrap™ Chromatin Immunoprecipitation technology receives positive commentary in published paper

Porvair Sciences reports on positive commentary by researchers in published papers citing how using the fast, sensitive ChromaTrap™ Chromatin Immunoprecipitation (ChIP) technology has benefited their research.

From Chromatrap® - Porvair Sciences Ltd 18 Mar 2014

WuXi Genome Center buys Illumina HiSeq X Ten sequencing system

Illumina, Inc. and WuXi PharmaTech (Cayman) Inc., a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company with operations in China and the United States, today announced that the WuXi Genome Center has purchased an Illumina HiSeq X Ten sequencing system.

From Illumina, Inc. 10 Mar 2014

Scientists develop reliable way of detecting prostate and bladder cancers

A new licence announced today between the University of Surrey and Randox, will bring to market a new test that will help with the early detection of prostate and bladder cancers.

From Randox Laboratories Ltd. 6 Mar 2014

Bio-Rad announces release of beta version of the USP Spectral Library

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostic products, today announced the release of beta version of USP Spectral Library™ powered by Bio Rad's KnowItAll® software technology platform for spectral analysis, identification, search, data management, and reporting.

From Bio-Rad Laboratories 5 Mar 2014

Nanomedicine – Past, Present and Future

News-Medical speaks to Frank Boehm about the fundamentals of nanomedicine and the nanotechnologies of the future.

4 Mar 2014

Maximizing imaging techniques to bridge the gap between diagnosis and treatment of cancer

Glioblastoma multiforme is the most common form of brain cancer and patients with this diagnosis have a life expectancy of less than two years. In spite of the fact that its diagnosis is very good, an appropriate treatment remains elusive.

From Bruker BioSpin - NMR, EPR and Imaging 3 Mar 2014

cfDNA testing lowers false positive rates and higher predictive values in general obstetric population

A study in this week's New England Journal of Medicine potentially has significant implications for prenatal testing for major fetal chromosome abnormalities. The study found that in a head-to-head comparison of noninvasive prenatal testing using cell free DNA (cfDNA) to standard screening methods, cfDNA testing (verifi- prenatal test, Illumina, Inc.) significantly reduced the rate of false positive results and had significantly higher positive predictive values for the detection of fetal trisomies 21 and 18.

From Illumina, Inc. 27 Feb 2014

Combining Nanophotonics and Microfluidics for the Characterization of Nanoparticles

In this interview, Bernardo Cordovez describes the development of a new nanophotonic chip that can be used to characterize nanoparticles.

From Halo Labs 24 Feb 2014

Biochrom launches EZ Nin Reagent for use in ion exchange chromatography systems

Biochrom Ltd, a manufacturer of quality scientific instruments for applications in the life science, clinical, and analytical markets, announced today the commercial launch of its EZ Nin ReagentTM, a ready-to-use ninhydrin formulation for use in ion exchange chromatography systems with post-column derivatisation for improved amino acid analysis.

From Biochrom Ltd. 24 Feb 2014

The Future of DNA Sequencing

In this interview, Barret Bready discusses the current gold standards in DNA sequencing and how the Nabsys platform is revolutionizing this process.

18 Feb 2014

Novogene purchases HiSeq X Ten sequencing system from Illumina

Illumina, Inc. (NASDAQ:ILMN) today announced that Novogene (www.novogene.cn), a leading genomics service provider based in Beijing, China, purchased one HiSeq X Ten.

From Illumina, Inc. 13 Feb 2014

Porvair Sciences to showcase specialist microplate products at Pittcon, Analytica and Genomics Research 2014

Porvair Sciences has announced that it will be showing its latest specialist microplates and microplate equipment at the forthcoming Pittcon 2014 (Chicago), Analytica 2014 (Munich) and Genomics Research 2014 (San Francisco) exhibitions.

From Chromatrap® - Porvair Sciences Ltd 11 Feb 2014

New Chromatrap Enzymatic Shearing Kit announced by Porvair Sciences

Porvair Sciences has announced a new Chromatrap Enzymatic Shearing Kit that contains all the necessary reagents and buffers for up to 10 chromatin preparations.

From Chromatrap® - Porvair Sciences Ltd 27 Jan 2014

Fluxion Biosciences announces release of IsoFlux Rare Cell Enrichment Kit

Fluxion Biosciences, Inc. announced the release of a new reagent kit for the IsoFlux System designed to provide more options for circulating tumor cell and other rare cell capture from biological samples. The IsoFlux Rare Cell Enrichment (Streptavidin) Kit incorporates streptavidin-coated magnetic beads that can bind with one or more biotinylated antibodies targeted towards cell-surface markers on the cells of interest.

From Fluxion Biosciences 21 Jan 2014

Illumina inks multi-year supply agreement with LabCorp

Illumina, Inc. today announced it has entered into a multi-year supply agreement with Laboratory Corporation of America Holdings. The agreement gives LabCorp expanded rights to use Illumina next-generation sequencing and microarray equipment and supplies to develop, validate and introduce laboratory-developed tests to clinicians in the United States and Canada.

From Illumina, Inc. 21 Jan 2014

Illumina signs multi-year licensing agreement with Quest Diagnostics

Illumina, Inc. today announced it has entered into a multi-year licensing agreement with Quest Diagnostics, the world's leading provider of diagnostic information services, related to the use of Illumina's next-generation sequencing technology for clinical laboratory testing.

From Illumina, Inc. 9 Jan 2014

Demand growing for Porvair Sciences' Chromatrap ChIP assay technology

Porvair Sciences reports strong growing demand for their Chromatrap chromatin immunoprecipitation (ChIP) assay technology from academic groups and biopharmaceutical organisations involved with epigenetic research.

From Chromatrap® - Porvair Sciences Ltd 6 Jan 2014

Fluxion Biosciences reports first study results from early stage NSCLC patients

Fluxion Biosciences, Inc. announced the presentation of the first pilot study results aimed at isolating circulating tumor cells (CTCs) from early stage non-small cell lung cancer (NSCLC) patients obtained in collaboration with Dr. Max Diehn's lab at Stanford University. CTCs are cells that disseminate from primary tumors and contribute to the spread of the disease to other parts of the body.

From Fluxion Biosciences 27 Nov 2013